DEA Considers Bulk Manufacturing of Psilocybin for Science
Published Date: 12/3/2025
Notice
Summary
Kinetochem LLC wants to become a big-time maker of some powerful controlled substances like marijuana and psilocybin for research and medicine. People and companies involved with these drugs can share their thoughts or ask for a hearing by February 2, 2026. This move could speed up scientific studies and drug development, with no direct cost changes announced yet.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
New Schedule I API supplier seeks registration
On October 15, 2025 Kinetochem LLC applied to be registered as a bulk manufacturer of Schedule I controlled substances including Marihuana (code 7360), Tetrahydrocannabinols (7370), Psilocybin (7437), and Psilocyn (7438). The company says it plans to bulk manufacture these drugs as Active Pharmaceutical Ingredients (APIs) for its customers and for research and clinical trials.
Synthetic-only manufacture for marijuana and THC
For drug codes 7360 (Marihuana) and 7370 (Tetrahydrocannabinols), Kinetochem plans to bulk manufacture these drugs as synthetic only, and the notice states that no other activities for these drug codes are authorized for this registration.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2025-21789, Proposed Information Collection Activity; ACF Performance Progress Report, ACF-OGM-SF-PPR-B
The Administration for Children and Families wants to keep using their Performance Progress Report form for three more years but with fewer questions to make it easier for grantees to fill out. This affects groups like state and local governments, tribes, nonprofits, and universities who get ACF grants. Comments on these changes are open until February 2, 2026, helping save time without cutting funding decisions.
Next: 2025-21793, Carbon and Certain Alloy Steel Wire Rod From China; Revised Schedule for the Subject Proceeding
The U.S. International Trade Commission is updating the timeline for reviewing carbon and certain alloy steel wire rod from China because of a government shutdown delay. Companies involved should note that the staff report is now out on November 19, 2025, and comments are due by November 26, 2025. This change could affect trade decisions and any related duties or tariffs.